The safety of ranitidine in elderly versus non-elderly patients.

Abstract

The authors conducted a retrospective review of 21 United States trials of ranitidine in acid peptic diseases and compared the adverse events in elderly (> or = 65 years) and nonelderly (< 65 years) patients. Ranitidine dosages ranged from 150 mg/day to 300 mg twice daily for treatment periods of 4 to 52 weeks. Of the 4041 patients included in this review… (More)

Topics

Cite this paper

@article{Sirgo1993TheSO, title={The safety of ranitidine in elderly versus non-elderly patients.}, author={M A Sirgo and R. Mills and Andr{\'e} Euler and S. Walker}, journal={Journal of clinical pharmacology}, year={1993}, volume={33 1}, pages={79-83} }